India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25 % of all medicine in UK. The pharmaceutical sector was valued at US$ 33 billion in 2017. The country's pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015-20 to reach US$ 55 billion. India's pharmaceutical exports stood at US$ 17.27 billion in FY18 and have reached US$ US$ 15.52 billion in FY19 (up to January 2019). Medicine spending in India is projected to grow 9-12 % over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.
Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.
In this limelight, CPhI Conferences is pleased to launch the Pharma Analytical Conclave on 08-09 August, 2019 at Novotel Hyderabad Convention Centre. A 2-day comprehensive conclave will commence with a Strategic Conference on innovation, regulatory updates and current challenges in pharma industry, along with parallel sessions on, Impurity Profiling, Aseptic Processing & Sterile Manufacturing. The key objective of this summit is to deliberate on most crucial topics to enlighten the R&D and manufacturing professionals in pharma and bio-pharma industry.
Dr. BM Rao
VP & Head – Analytical Science & Technology & CQC
Dr. Reddy's Laboratories
Dr. Olivier Chancel
Sterility and Aseptic Practices Expert and Senior Quality Auditor
Dr. Chetan Doshi
Chief Scientific Officer
USV Private Limited
Dr. Atul Awasthi
Director - GTS MSAT AS
Senior Vice President, India Quality Management
Dr. Vandana Singh
Director in Advanced Characterisation Laboratories
Dr. Reddy’s Laboratories Ltd.
Senior Vice President- API Operations
Senior Vice President
Mankind Pharma Ltd.
Dr. Ajay J. Khopade
Vice President-R&D, Formulation Development (Non-Orals)
Sun Pharma Advanced Research Co. Ltd.
Vice President Analytical R&D
Dr. PV Appaji
Retired First – Director General
Director -Technology Transfer
Head, Product and Portfolio Development (India), Global Parenteral Product Development
Dr. Hemant Bhutani
Head, Analytical R&D
Dr. Kailash Chandra Asati
Global Senior Stability Expert- Analytical Research Development, Global Drug Development / Technical Research & Development
Novartis Healthcare Pvt. Ltd.
Dr. Tushar N. Mehta
Associate Vice President
Dr. Anil K. Binnor
Associate Vice President & Head- AR&D
Associate Director- QbD- IPD
Dr. Tarun Chugh
SIMco Pharma Consultancy
Dr. Anoop Kumar
Market Development Manager
Pharma/CROs/Biopharma SCIEX, India
Central Drugs Standard Control Organization
Field Marketing Manager
Dr. Ganesh Prasad
Q_Pharma Consulting India
Madhu Sudhan Rao Rachakonda
Hetero Drugs Ltd
Pharma Analytical Conference is a 2-day strategic summit to address the most critical, technical and commercial challenges along with the way forward in the R&D and manufacturing domain.
Impurity Profiling workshop will focus on details delineated in the ICH M7 and Q3D guidelines and elaborate on the challenges that industry is experiencing when attending elemental and genotoxic impurities in drug substances and drug products.
Aseptic Processing and Sterile Manufacturing workshop will deliberate on technological advancements and key innovations in aseptic processing and sterilization processes.
Hyderabad is a very big hub for pharma industry. PharmaLytica is conducive to pharma growth since it includes production area, analytical area, R&D and instrumentation. So customers are happy to see all this.Arun kumar
Zonal sales manager
Borosil Glass Works
My experience with CPhI conference: It has been a good interactive conference where many of my queries were well answered and resolvedManager
The conference was good which covers the important topics on Genotoxic impurities wherein the speakers have also clarified many of our concerns that really will help us to move ahead in our routine work to identify, evaluate and limit these genotoxic impurities in drug substance & drug product.Dr. Nitesh Kanyawar
All presentations were informative. It enlightened me with the regulatory requirements for the biosimilars development, approach of US FDA and EMA, ICH guidelines for the characterization procedures and many technical, non-technical factors involved in development and post-developmental phases. Also, realized the development in the laboratory and manufacturing technologies.Hrishikesh Joshi
Got information on the biosimilarity requirements for USFDA based on industry experience. Expectations for Analytical similarity requirements. Clarity on clinical trial requirements for below 40 amino acid biologicals. An Opportunity to network with the delegatesShoba Shenoy
Senior Asst General Manager - Biologics
USV Private Ltd